Board of Directors

Sandeep Laumas, M.D.
Executive Chairman
Sandeep Laumas
Dr. Laumas joined Innovate Biopharmaceuticals in 2014 as Executive Chairman.  Dr. Laumas founded Bearing Circle Capital in 2008 and has been its Chief Executive Officer since 2008. He started his career at Goldman Sachs in 1996 as an equity analyst in the Healthcare Investment Banking division working on mergers, acquisitions, and corporate finance transactions before transitioning to the Healthcare Equity Research division. After leaving Goldman Sachs in 2000, Dr. Laumas moved to the buy side as an Analyst at Balyasny Asset Management from 2001 to 2003. Dr. Laumas was the Managing Director of North Sound Capital from 2003 to 2007, where he was responsible for their global healthcare investment portfolio. Since February 2011, he has been a Director for Super Religare Laboratories Limited, Southeast Asia’s largest clinical laboratory. Dr. Laumas also served as a Director of Parkway Holdings Ltd. (IHH Healthcare Bhd.: Singapore: IHH) from May through August 2010. Dr. Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. in Medicine from Albany Medical College in 1995 and completed his medical internship in 1996 from the Yale University School of Medicine.
Chairman of the Board
Christopher P. Prior, Ph.D.
Chief Executive Officer
Christopher P. Prior
Dr. Prior is a recognized industry leader both as a developer of important new therapeutics and as an accomplished serial entrepreneur. Over the course of his 30-year career, he has generated more than 25 INDs and achieved four product approvals. In addition, he founded, built-up and sold two companies (Principia, BioRexis) in deal values exceeding $0.5 Billion. Chris joined Innovate in 2015 as Chief Executive Officer. Chris received a B.Sc. (honors) in chemistry from the University of London, a Ph.D. in biochemistry from Columbia University in New York City and a research fellowship at The Rockefeller Medical Institute (New York). Chris is a member of the New York Academy of Sciences and is the author of numerous publications and patents focused on the development of therapeutics.
Jay P. Madan, M.S.
Founder, President and Chief Business Officer
Jay P. Madan
Mr. Madan founded Innovate Biopharmaceuticals in 2013 and has spent more than two decades in life sciences/biotech as a leader in M&A, technology transfer, cross border licensing and project development.  Mr. Madan’s experience in working across multiple teams at Reliance Life Sciences, Millipore, Baxter, Dade Behring, and Goodwin led him to develop a global network of healthcare professionals. He was the VP of Business Development at Reliance Biopharmaceuticals Pvt. Ltd. part of Reliance Industries Ltd., India’s largest conglomerate. Both at Reliance and Goodwin, he was focused on the development of their contract manufacturing businesses. Mr. Madan holds a Bachelor of Chemical Engineering from University of Mumbai and an M.S. in Chemical Engineering from Washington State University.
Financial Expert
Lorin K. Johnson, Ph.D.
Lorin K. Johnson

Dr. Johnson is the founder and Chief Scientist of Glycyx PharmaVentures Ltd. He co-founded Salix Pharmaceuticals, Inc. (NASDAQ: SLXP) and held senior leadership positions prior to its $15.8 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX). Prior to Salix, Dr. Johnson served as Director of Scientific Operations and Chief Scientist at Scios, Inc. (Formerly, California Biotechnology, Inc.). He is a Director of Sigmoid Pharma Ltd. In addition to his career in industry, Dr. Johnson has served as an Assistant Professor of Pathology at Stanford University Medical Center and held academic positions at Stanford University School of Medicine and the University of California, San Francisco. He is the co-author of 75 journal articles and book chapters and is the co-inventor on 18 issued patents. Dr. Johnson holds a PhD from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco.

Independent Director
Anna Kazanchyan, M.D.
Anna Kazanchyan
Dr. Kazanchyan founded Saghmos Therapeutics, a company focused on the prevention of contrast-induced acute kidney injury, in September 2016 and serves as its CEO and Chairwoman. Dr. Kazanchyan has served as a member of the board of directors of Foamix Pharmaceuticals (NASDAQ: FOMX) since December 2014 and currently serves on its compensation committee.  She is also the founder and Managing Partner since April 2004 of Primary i-Research, LLC, where she provides due diligence to leading healthcare investment funds and evaluates investment prospects of biopharmaceutical companies based on the scientific, clinical, regulatory, and commercial outlook for their products.  In addition, she has been a strategic advisor to CEOs of biopharmaceutical companies (start-ups to global companies) and has advised companies on matters related to business development, regulatory strategy, marketing, and commercial/competitive landscape. From 2014-2016, Dr. Kazanchyan was SVP, Business Development and Product Development at Ovid Therapeutics, Inc. (NASDAQ: OVID), a company focused on rare neurological disorders. Previously, Dr. Kazanchyan was Senior Biotechnology Analyst at Wachovia Securities, and was a member of the #1 and #2 Institutional-Investor ranked Biotechnology Equity Research teams at Goldman Sachs and Citigroup, respectively. She received an M.D. from Harvard Medical School and a B.A. in Biology, summa cum laude, from Clark University.
Independent Director
Anthony E. Maida III, PhD, MA, MBA
Anthony E. Maida III

For 25 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer.

Dr. Maida is currently Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer. Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc. Prior to coming to Pharmanet, Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions.

Over the past 18 years Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development. Dr. Maida was formerly the President and CEO of Replicon NeuroTherapeutics, Inc., a biopharmaceutical company focused on the therapy of patients with tumors (both primary and metastatic) of the CNS.

Prior to Replicon Dr. Maida served as Interim CEO for Trellis Bioscience, Inc. In 2000 Dr. Maida served as President of CancerVax Corporation. Over recent years Dr. Maida has raised, or assisted in financings, in excess of $200 million for start-up and emerging biotechnology companies. Dr. Maida was President and Chief Executive Officer of Jenner Biotherapies, Inc., and has served as Vice President of Finance and CFO for Lockheed DataPlan, a wholly owned subsidiary, and Senior Financial Controller of Lockheed Missiles, a $1.7 billion division, of Lockheed Missiles and Space Company.

Dr. Maida serves or has served on the advisory board of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia), and as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and Pediatric BioScience, Inc.

Dr. Maida holds a B.A. degree in Biology, a B.A. Degree in History, a MBA, a MA in toxicology and a Ph.D. in Immunology. He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTc) and the American Chemical Society. Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.

Independent Director
Roy Proujansky, MD
Roy Proujansky

He received his undergraduate degree and his medical degree from Northwestern University in Chicago. He subsequently trained in Pediatrics at the University of Connecticut. Dr. Proujansky completed a Clinical and Research fellowship in the Combined Program in Gastroenterology and Nutrition at the Children’s Hospital, Massachusetts General Hospital, Harvard Medical School and a Research Fellowship in Infectious Diseases in the Combined Infectious Disease Training Program at Harvard Medical School. Upon completion of his training, Dr. Proujansky joined the faculty at the Children’s Hospital of Pittsburgh as Assistant Professor of Pediatrics at University of Pittsburgh School of Medicine.

Dr. Proujansky was appointed Chief Executive of all Nemours Delaware Valley Operations in 2013, including Nemours/Alfred I. duPont Hospital for Children. As Chief Executive of Delaware Valley Operations, he is responsible for all clinical operations at Nemours/Alfred I. duPont Hospital for Children, Nemours duPont Pediatrics and prevention efforts in the Delaware Valley. Dr. Proujansky is based in Wilmington, Del., and reports directly to Nemours President and Chief Executive Officer, David J. Bailey, MD, MBA.

He joined Nemours in 1989 as Chief of the Division of Gastroenterology and Nutrition at the Nemours/Alfred I. duPont Hospital for Children. In 1999, he was named the Chief Executive of the Practice, Nemours duPont Pediatrics (formerly Nemours Children’s Clinic) in Wilmington in the Delaware Valley. From 2000 — 2006 he also served as the Robert L. Brent Professor and Chairman, Department of Pediatrics, and Associate Dean, Jefferson Medical College (Philadelphia).

In 2005, Dr. Proujansky was appointed to the Executive Group as a Vice President of Nemours, and in 2006 became Executive Vice President, Patient Operations and Chief Operating Officer of Nemours responsible for all patient care, research, prevention and education activities.

Independent Director

Copyright Nasdaq. Minimum 15 minutes delayed.